Cardiac enzymes: Difference between revisions
No edit summary |
No edit summary |
||
| (15 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
== | ==Types== | ||
{{Cardiac enzyme timecourse chart}} | |||
{ | |||
==Creatine Phosphokinase== | ==Creatine Phosphokinase== | ||
*Can be elevated in trauma, [[rhabdomyolysis]], hyperthermia, physical activity, renal or endocrine disease, systemic infections | |||
*If patient small with small muscle mass to begin with, total ck may not be elevated- so better to use CK index- is ratio of CKMB/ total CK. Elevated if > 3- 5%. | |||
*CK Mass: with monoclonal antibody techniques, can directly measure ck mb mass as mmcg/L. More sensitive for detection of AMI | |||
*CK-MB can be removed from the routine ED cardiac panel without adversely affecting patient care<ref>Le RD, Kosowsky JM, Landman AB, et al. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015;33(1):72–5. </ref> | |||
- | |||
- | |||
==See Also== | ==See Also== | ||
*[[Troponin]] | |||
*[[Acute Coronary Syndrome (Main)]] | |||
==References== | |||
<references/> | |||
[[Category:Cardiology]] | |||
Latest revision as of 18:06, 27 October 2016
Types
Cardiac Enzymes Over Time
| Type | Interval (hours) | Peak Elevation (hours) | Return to Normal |
| Myoglobin | 1-4 | 6-7 | 18-24 hours |
| Troponin I | 3-12 | 10-24 | 3-10 days |
| Troponin T | 3-12 | 10-24 | 5-14 days |
| CK-MB | 4-12 | 12-24 | 2-3 days |
| LDH | 8-12 | 24-48 | 10-14 days |
Creatine Phosphokinase
- Can be elevated in trauma, rhabdomyolysis, hyperthermia, physical activity, renal or endocrine disease, systemic infections
- If patient small with small muscle mass to begin with, total ck may not be elevated- so better to use CK index- is ratio of CKMB/ total CK. Elevated if > 3- 5%.
- CK Mass: with monoclonal antibody techniques, can directly measure ck mb mass as mmcg/L. More sensitive for detection of AMI
- CK-MB can be removed from the routine ED cardiac panel without adversely affecting patient care[1]
See Also
References
- ↑ Le RD, Kosowsky JM, Landman AB, et al. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015;33(1):72–5.